Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]